Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own0.40% Shs Outstand45.60M Perf Week-1.32%
Market Cap135.89M Forward P/E- EPS next Y-0.92 Insider Trans8.96% Shs Float44.32M Perf Month9.56%
Income-25.40M PEG- EPS next Q-0.22 Inst Own66.60% Short Float10.43% Perf Quarter-20.95%
Sales22.10M P/S6.15 EPS this Y28.30% Inst Trans-0.06% Short Ratio14.70 Perf Half Y-3.25%
Book/sh0.52 P/B5.73 EPS next Y-3.40% ROA-22.80% Target Price7.05 Perf Year-32.58%
Cash/sh2.35 P/C1.27 EPS next 5Y- ROE-78.10% 52W Range2.40 - 5.88 Perf YTD-22.60%
Dividend- P/FCF- EPS past 5Y5.70% ROI-38.20% 52W High-49.32% Beta2.15
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin75.70% 52W Low24.17% ATR0.16
Employees36 Current Ratio6.70 Sales Q/Q1571.30% Oper. Margin-77.70% RSI (14)51.01 Volatility4.39% 5.64%
OptionableYes Debt/Eq3.71 EPS Q/Q-6.10% Profit Margin- Rel Volume0.54 Prev Close2.94
ShortableYes LT Debt/Eq3.31 EarningsAug 01 AMC Payout- Avg Volume314.39K Price2.98
Recom2.20 SMA204.93% SMA50-2.87% SMA200-18.03% Volume170,581 Change1.36%
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Dec-17-13Reiterated MLV & Co Buy $15 → $16.50
Jul-17-13Reiterated Mizuho Neutral $13 → $18
Feb-04-13Initiated MLV & Co Buy $13
Jul-20-16 12:05PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 20, 2016
Jul-08-16 06:09AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jul-06-16 07:00AM  AcelRx Pharmaceuticals to Present at Cantor Fitzgerald 2nd Annual Healthcare Conference PR Newswire
Jun-28-16 07:00AM  AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain PR Newswire
Jun-27-16 07:00AM  AcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes PR Newswire
Jun-22-16 04:06PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -5.23%
Jun-21-16 04:32PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Jun-02-16 07:00AM  AcelRx Pharmaceuticals to Participate in Three Upcoming Healthcare Investor Events in June PR Newswire
May-26-16 07:00AM  AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX04 following Ambulatory Abdominal Surgeries at Euroanaesthesia PR Newswire
May-24-16 07:00AM  New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140 PR Newswire
May-19-16 06:52PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 19, 2016
May-17-16 01:46PM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2016 By the Numbers
May-07-16 01:04PM  ACELRX PHARMACEUTICALS INC Financials
May-06-16 07:00AM  AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX04 by Type of Abdominal Surgery PR Newswire
May-04-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May PR Newswire
06:18AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-03-16 01:16AM  Edited Transcript of ACRX earnings conference call or presentation 2-May-16 8:30pm GMT
May-02-16 05:16PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
04:53PM  AcelRx Pharmaceuticals reports 1Q loss
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close CCBN
Apr-28-16 07:00AM  AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016 PR Newswire
Apr-12-16 08:30AM  AcelRx Pharmaceuticals (ACRX): Strong Industry, Solid Earnings Estimate Revisions
Mar-31-16 06:16AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-30-16 06:23AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-29-16 04:00PM  AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016 PR Newswire
Mar-25-16 07:00AM  AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics PR Newswire
Mar-24-16 05:44PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 24, 2016
Mar-14-16 04:44PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
04:34PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 14, 2016
10:38AM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2015 By the Numbers
07:00AM  AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study PR Newswire
Mar-09-16 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-07-16 11:56PM  Edited Transcript of ACRX earnings conference call or presentation 7-Mar-16 9:30pm GMT
05:07PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:19PM  AcelRx Pharmaceuticals reports 4Q loss
04:01PM  AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results PR Newswire
07:07AM  Q4 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
07:00AM  AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain PR Newswire
Mar-04-16 06:08AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-03-16 07:00AM  AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016. PR Newswire -5.80%
Mar-01-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March PR Newswire
Feb-25-16 10:15AM  4 Stocks That Are Starting To Attract Major Attention Today Accesswire
07:00AM  AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis PR Newswire
06:49AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-19-16 04:54PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +6.63%
Feb-17-16 04:57PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Feb-11-16 07:00AM  AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium PR Newswire
Feb-03-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February PR Newswire
Jan-21-16 07:00AM  AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery PR Newswire +7.58%
Jan-11-16 10:04AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur -8.72%
Jan-10-16 07:00AM  AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones PR Newswire
Jan-08-16 07:02AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso in 1Q 2016 PR Newswire
Dec-23-15 07:00AM  AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency PR Newswire
Dec-14-15 01:50PM  AcelRx Tanks on Pre-NDA Results -20.39%
07:02AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 PR Newswire
Dec-08-15 11:39AM  Should You Avoid AcelRx Pharmaceuticals Inc (ACRX)? at Insider Monkey
Nov-27-15 03:19PM  Abraxas Petroleum Corp. (AXAS): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-23-15 07:00AM  AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference PR Newswire +7.06%
Nov-19-15 08:50AM  A Look at Equity Market Momentum - Research on Multi-Fineline Electronix, AcelRx Pharmaceuticals, CAI International and Peregrine Pharmaceuticals Accesswire
07:09AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting
07:00AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting PR Newswire
Nov-10-15 07:00AM  AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference PR Newswire
Nov-05-15 07:00AM  AcelRx Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference PR Newswire -5.99%
Nov-04-15 07:00AM  AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients PR Newswire +7.08%
Nov-03-15 06:09AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-02-15 06:55AM  Where Opportunity is Found - Research on AcelRx Pharmaceuticals, Tandem Diabetes Care, Brightcove and SciQuest Accesswire +11.17%
06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-30-15 09:24PM  Edited Transcript of ACRX earnings conference call or presentation 29-Oct-15 8:30pm GMT +17.61%
01:25PM  5 Analyst Upgrades That Were Too Big to Ignore at 24/7 Wall St.
Oct-29-15 05:29PM  AcelRx Pharmaceuticals tops Street 3Q forecasts
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:10PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results PR Newswire
07:07AM  Q3 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Oct-26-15 07:00AM  AcelRx Pharmaceuticals to Hold Business Update and Third Quarter Financial Results Conference Call and Webcast on Thursday, Oct 29th, 2015 PR Newswire
Oct-23-15 07:00AM  AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The American Society Of Anesthesiology Meeting PR Newswire
Oct-09-15 12:08PM  IMMU and ACRX Outperform in the Biotech Downdraft
07:00AM  AcelRX Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting PR Newswire
Oct-08-15 05:00PM  AcelRx Updates on Zalviso for Pain Management Treatment -5.45%
07:01AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso PR Newswire
Oct-06-15 07:00AM  AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain PR Newswire
Oct-02-15 05:23PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +9.06%
10:43AM  Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters at TheStreet
Oct-01-15 11:07AM  AcelRx Pharmaceuticals, Inc. Earnings Q2, 2015
09:30AM  New Strong Buy Stocks for October 1st
08:22AM  AcelRx Pharmaceuticals (ACRX) Enters Oversold Territory
07:00AM  AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy PR Newswire
Sep-29-15 09:30AM  New Strong Buy Stocks for September 29th
Sep-24-15 03:25PM  PDL BioPharma Concludes Financing Agreement with Avinger
07:00AM  AcelRx Pharmaceuticals to Host Analyst & Investor Event on October 2, 2015 PR Newswire
Sep-23-15 04:00PM  AcelRx's Pain Treatment Drug Zalviso Approved in Europe
Sep-22-15 05:58PM  PDL BioPharma to Get Royalties on AcelRx's Zalviso Sales
02:57PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:41AM  AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients PR Newswire
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain in the United States. The company's lead product candidates include ARX-04, a sufentanil sublingual tablet that is in Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings; and Zalviso, a sufentanil sublingual tablet system, which is in Phase III clinical trials for the treatment of moderate-to-severe acute pain in hospitalized adult patients. It is also developing ARX-03, a fixed-dose sufentanil/triazolam sublingual tablet, which has been completed Phase II clinical trial for mild sedation and pain relief during painful procedures. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EDWARDS MARK GDirectorMay 12Buy3.055,00015,250115,000May 12 06:40 PM
EDWARDS MARK GDirectorMay 11Buy3.155,00015,750110,000May 12 06:40 PM
EDWARDS MARK GDirectorMay 10Buy3.255,00016,250105,000May 12 06:40 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 18Sale5.3542,300226,1325,995,760Nov 19 04:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 17Sale5.36133,900717,4096,038,060Nov 19 04:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 06Sale4.4717,10076,3656,171,960Nov 09 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 05Sale4.6275,000346,2606,189,060Nov 09 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 09Sale4.18310,0001,294,7776,264,060Sep 11 04:01 PM